A compound, or its optical isomer, pharmaceutically acceptable salt, pharmaceutical product, N- oxide, hydrate or any combination thereof, represented by the structure of Formula VI: wherein R 1 is hydrogen； R 2 is hydrogen, COOH, -C(=NH)-OH, -CH=CH 2 , hydroxyl, cyano, OCOR, alkenyl, OSO 2 CF 3 , or protected hydroxyl； R 3 , R 8 and R 9 are hydrogen； R 10 is hydrogen, halogen, CH=CHCO 2 H, CH=CHCO 2 R, -CH=CH 2 , cyano, aryl, 4-methoxyphenyl, 4-hydroxyphenyl, alkenyl, alkyl, or haloalkyl； R 11 is hydrogen, halogen, cyano, or SO 2 R； R 6 is hydrogen, halogen, or C 1 -C 6 -alkyl； R 7 is hydrogen or halogen； R' is hydrogen, Alk or COR； R" is hydrogen, Alk or COR； and R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, aryl, benzyl, halogen, alkenyl, CN, or NO 2 ； and Alk is a linear alkyl of 1-7 carbons, branched alkyl of 1-7 carbons, or cycloalkyl of 3-8 carbons； for use in treating, delaying onset, reducing the incidence of, or reducing the severity of a fatty liver condition in a subject.
